Cash/Burn From SEC Filing For Period: 


Dynavax Technologies

Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. Dynavax develops, and commercializes novel vaccines.



Burn Rate


Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data


Hepatitis B Vaccine

Quarterly Sales (Approved)

October 23, 2020 (Est)

SARS-CoV-2 Inactivated Vaccine (with Sinovac)

COVID-19 Vaccine

Phase 3 Readout


COVID-19 Vaccine (with Medicago)

COVID-19 Vaccine

Phase 1 (Preliminary safety and immunogenicity results)

October 2020 (Est)

COVID-19 S-Trimer (with Clover Biopharmaceuticals)

COVID-19 Vaccine

Phase 1


Vaccine Candidate (with Valneva)

COVID-19 Vaccine



Vaccine Candidate (with Coalition for Epidemic Preparedness Innovations (CEPI) and Queensland)

COVID-19 Vaccine



Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon